Pharvaris (PHVS) EBITDA (2020 - 2026)

Pharvaris (PHVS) has 7 years of EBITDA data on file, last reported at -$51.8 million in Q1 2026.

• Quarterly EBITDA rose 100.0% year-over-year to -$51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$305.3 million (up 100.0% YoY) and the FY2025 annual result came in at -$196.3 million, down 36.96% from the prior year.
• EBITDA rose to -$51.8 million in Q1 2026, from -$202.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$46.37 in Q3 2025 to a low of -$44375124102.2 billion in Q1 2025.
• A 5-year average of -$2610304572.9 billion and a median of -$51.3 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2025 — EBITDA plunged 144276773.01% — and 2026, when it surged 100.0%.
• Tracing PHVS's EBITDA over 5 years: stood at -$77.2 million in 2022, then plunged by 332973.03% to -$257.1 billion in 2023, then jumped by 99.94% to -$141.5 million in 2024, then plunged by 42.92% to -$202.2 million in 2025, then jumped by 74.37% to -$51.8 million in 2026.
• The last three EBITDA figures came in at -$51.8 million (Q1 2026), -$202.2 million (Q4 2025), and -$46.37 (Q3 2025), per Business Quant data.